Sequencing Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
For patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), clinical decision-making focuses on selecting subsequent lines of systemic therapy. Treatment selection is currently guided by molecular profiling, prior treatment history, and patient-specific factors, according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Prostate Cancer.
Molecular Profiling and Targeted Therapy
Modern management of mCRPC increasingly relies on identifying genomic alterations that dictate the use of targeted agents. According to the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, germline and somatic testing for homologous recombination repair (HRR) gene mutations—such as BRCA1, BRCA2, and ATM—is recommended for all patients with metastatic disease. If these mutations are present, poly (ADP-ribose) polymerase (PARP) inhibitors, such as olaparib or rucaparib, may be utilized as subsequent lines of therapy.
Taxane-Based Chemotherapy Options
For patients who do not harbor actionable genomic alterations or who have progressed after targeted therapy, taxane-based chemotherapy remains a cornerstone of treatment. Docetaxel is frequently employed as the first-line chemotherapy for mCRPC, particularly in patients who have not received it in the hormone-sensitive setting. Following progression on docetaxel, cabazitaxel is a standard option. The TROPIC trial established the efficacy of cabazitaxel in improving overall survival for patients whose disease progressed on docetaxel, providing a verified pathway for sequential chemotherapy.
Radioligand Therapy Implementation
Lutetium Lu 177 vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, has emerged as a significant option for patients with PSMA-positive mCRPC. Based on results from the VISION trial, this therapy is indicated for patients who have previously received both an ARPI and taxane-based chemotherapy. The sequencing of radioligand therapy relative to other agents remains a subject of ongoing clinical investigation, though it is currently positioned as a later-line treatment for patients with documented PSMA expression on PET/CT imaging.
Comparative Treatment Considerations
| Treatment Category | Primary Indicator | Clinical Context |
|---|---|---|
| PARP Inhibitors | HRR Gene Mutations | Post-ARPI progression |
| Taxane Chemotherapy | General mCRPC progression | Standard after ARPI failure |
| Radioligand Therapy | PSMA-positive disease | Post-ARPI and post-taxane |
Clinical Strategy and Future Directions
The sequencing of these agents is not strictly linear and requires a multidisciplinary approach. According to the American Urological Association (AUA) guidelines, clinicians must balance the potential for survival benefits against the toxicity profiles of each agent. Future treatment strategies are shifting toward earlier integration of these therapies and the exploration of combination regimens to overcome resistance mechanisms. As clinical trials continue to report data on cross-resistance between ARPIs and newer agents, the hierarchy of care continues to evolve, emphasizing the necessity of updated molecular testing at each stage of disease progression.